Open Access<p>Docosahexaenoic Acid Serving As Sensitizing Agents And Gefitinib Resistance Revertants In EGFR Targeting Treatment</p>
Author(s) -
Xiaowen Ding,
Ge Liu,
Aiwen Yan,
Yuyin Ding,
Junye Tao,
Qianqian Liu,
Chunxia Qiao
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s225918
Subject(s) - gefitinib , docosahexaenoic acid , medicine , pharmacology , cancer research , chemistry , fatty acid , biochemistry , epidermal growth factor receptor , polyunsaturated fatty acid , cancer
Due to the resistance of cancer cells, chemotherapy has been severely restricted. Docosahexaenoic acid (DHA) has been broadly identified as the chemo-sensitizing agent and revertant of multidrug resistance owing to its pleiotropic characteristics; however, it has not been well interpreted. The purpose of this research was to identify the anticancer role of DHA and its combination with the chemotherapeutic agent Gefitinib in non-small cell lung cancer (NSCLC).